United States securities and exchange commission logo
June 6, 2024
Amro Albanna
Chief Executive Officer and Chairman of the Board of Directors
Aditxt, Inc.
737 N. Fifth Street, Suite 200
Richmond, VA 23219
Re: Aditxt, Inc.
Preliminary Proxy
Statement on Schedule 14A
Filed May 29, 2024
File No. 001-39336
Dear Amro Albanna:
We have reviewed your
filing and have the following comments.
Please respond to this letter within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe a
comment applies to your facts and circumstances, please tell us why in
your response.
After reviewing your
response to this letter, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
Proposal No. 8: The Authorized Share Increase Proposal, page 54
1. Please revise here and
throughout your preliminary proxy statement to quantify the
proposed increase to
the number of authorized shares of common stock.
Proposal No. 9: The Reverse Split Proposal, page 56
2. Please revise here and
throughout your preliminary proxy statement to disclose the range
of the proposed reverse
stock split.
General
3. We note that Proposal 3
is a solicitation of your stockholders for the issuance of shares of
common stock underlying
shares of Series A-1 Convertible Preferred Stock issued
pursuant to the Merger
Agreement and Exchange Agreement with Evofem Biosciences,
Inc. in December 2023.
In addition, we note Proposal 6 is a solicitation of your
stockholders for the
issuance of shares of common stock underlying shares of Series C-1
Amro Albanna
Aditxt, Inc.
June 6, 2024
Page 2
Convertible Preferred Stock issued to fund certain obligations under
[your] merger
agreement with Evofem Biosciences, Inc. in May 2024. Please revise
your preliminary
proxy statement to provide the disclosures required by Items 11, 13 and
14 of Schedule
14A with respect to those matters, as applicable, pursuant to Note A of
Schedule 14A.
Alternatively, please provide us with analysis supporting why such
disclosure is not
required.
We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
Please contact Daniel Crawford at 202-551-7767 or Jason Drory at
202-551-8342 with
any other questions.
Sincerely,
FirstName LastNameAmro Albanna
Division of
Corporation Finance
Comapany NameAditxt, Inc.
Office of Life
Sciences
June 6, 2024 Page 2
cc: Sean Reid, Esq.
FirstName LastName